Why is Rheinmetall stock sliding today?

Rheinmetall cut 2026 revenue guidance to approximately €13.2B from €13.7–14.2B, reduced its operating-margin target to around 18.5% from 19%, and effectively abandoned its cash-conversion goal, now just above 0% versus more than 40%. Shares fell nearly 7% to €880 and touched a 52-week low of €870 after delays to the Arminius Boxer contract and artillery ammunition approvals; JPMorgan lowered its price target to €1,150 from €1,350 and retained a Neutral rating with a Negative Catalyst Watch. The warning contrasts with Q3 operating profit growth of 62%, while sector pressure tied to concerns over future U.S. military spending added to the decline.

Analysis

The important signal is not the deferred revenue by itself, but the combination of repeated schedule slippage and the loss of cash-conversion visibility. If approvals and commissioning simply move into next year, the earnings impact may be recoverable; if customers are slowing acceptance or Rheinmetall is struggling to execute, both revenue timing and cash receipts could remain unreliable. That distinction matters more to the multiple than one quarter’s operating growth. The company’s guidance is management’s estimate, not independent confirmation that the work will be delivered on the revised timetable.

Near term, a lower share price and sector-wide political risk can amplify each other: investors may demand a larger execution discount precisely when the defense-growth trade is losing momentum. In the next 1–3 months, watch for evidence on Boxer commissioning, ammunition batch approvals, and cash conversion—not just order announcements. Over 6–18 months, persistent slippage could redirect investor preference toward defense suppliers perceived as having more diversified programs or steadier delivery, including BAE Systems, Leonardo, and Saab; this is a relative-quality hypothesis, not evidence of immediate share gains.

Contrarian case: the deferrals may be timing rather than lost demand, leaving scope for a recovery if milestones clear. But after repeated guidance changes, a quick rebound based solely on that explanation is hard to underwrite. No valuation or consensus data are provided, so the selloff cannot be called excessive on fundamentals alone.

Key Decisions for Investors

• Avoid averaging down in RHM until the company demonstrates progress on commissioning and ammunition approvals and restores credible cash-conversion guidance. Treat those milestones, rather than headline order intake, as the thesis test.
• For an existing RHM position, consider reducing exposure or hedging part of it against further execution and sector-policy repricing; the shares’ weakness does not by itself establish a price floor.
• A relative-value long in BAE Systems, Leonardo, or Saab versus short RHM is a watch-list idea, not an immediate recommendation: first verify comparable valuation, program exposure, and delivery performance, and size for broad European defense-sector risk.
• Falsifiers: confirmed commissioning and approvals on the revised schedule, improving cash conversion, and guidance stability would weaken the bearish execution thesis. Further schedule slips or another outlook cut would strengthen it.